Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

BACKGROUND: Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next‐generation hypomethylating agent, could be useful in treating such patients. METHODS: In this multicenter, open‐label, phase 2 dose‐expansion study, AML patients from 10 North A...

Descripción completa

Detalles Bibliográficos
Autores principales: Roboz, Gail J., Kantarjian, Hagop M., Yee, Karen W. L., Kropf, Patricia L., O'Connell, Casey L., Griffiths, Elizabeth A., Stock, Wendy, Daver, Naval G., Jabbour, Elias, Ritchie, Ellen K., Walsh, Katherine J., Rizzieri, David, Lunin, Scott D., Curio, Tania, Chung, Woonbok, Hao, Yong, Lowder, James N., Azab, Mohammad, Issa, Jean‐Pierre J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814873/
https://www.ncbi.nlm.nih.gov/pubmed/29211308
http://dx.doi.org/10.1002/cncr.31138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814873/
https://www.ncbi.nlm.nih.gov/pubmed/29211308
http://dx.doi.org/10.1002/cncr.31138

Ejemplares similares